Axoltis Pharma’s Post

Meet Axoltis Pharma at BIO 2026 Axoltis Pharma will be attending the BIO International Convention, one of the world’s leading biotechnology partnering events. 📅 June 22-25, 2026 📍 San Diego Convention Center Yann GODFRIN, Ph.D., CEO of Axoltis Pharma and Luca Bolliger, Chief Business Officer, will be on site and available for partnering discussions throughout the convention. We are proud to join the French delegation alongside more than 100 companies, with the support of Business France Healthcare - North America. Axoltis Pharma is a Phase 2 clinical-stage biotech advancing NX210c, under evaluation in a Phase 2 clinical trial in patients with ALS,  with potential in Blood-Brain Barrier (BBB) integrity restoration, neuroprotection and neurotransmission. 👉 Let’s connect in San Diego and explore partnership opportunities #BIO2026 #Biotech #Pharma #ALS #ClinicalTrials #DrugDevelopment

  • No alternative text description for this image

To view or add a comment, sign in

Explore content categories